AbbVie Partners with Neomorph to Develop Novel Molecular Glue Degraders for Cancer and Immune Disorders, with Up to $1.64B in Potential Milestones

North Chicago, IL and San Diego, CA, January 23, 2025 (PRNewswire) -- AbbVie has partnered with Neomorph to develop molecular glue degraders for cancer and immune disorders, with Neomorph eligible for up to $1.64 billion in payments. The collaboration combines AbbVie’s expertise with Neomorph’s innovative molecular glue platform. These degraders aim to target previously “undruggable” proteins, potentially revolutionizing treatment strategies.

Read full article here.